Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442278 | 0.89 | APOBEC3G (0.73) | APOBEC3GSLC6A4SLC6A2LDHAIFNAR1 | |
| SCHEMBL74169 | 0.89 | SLC6A2 (0.47) | APOBEC3GSLC6A4SLC6A2IFNAR1SLC6A3 | |
| SCHEMBL12090255 | 0.82 | P4HB (0.57) | SLC6A4SLC6A2SLC6A3GABRA1GABRB2 | |
| SCHEMBL13579946 | 0.82 | APOBEC3G (0.57) | APOBEC3GSLC6A4SLC6A2IFNAR1SLC6A3 | |
| SCHEMBL21417607 | 0.81 | SLC6A4 (0.42) | SLC6A4SLC6A2IFNAR1SLC6A3GABRA1 | |
| SCHEMBL18795670 | 0.81 | SLC6A4 (0.48) | APOBEC3GSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30711874 | 0.81 | SLC6A4 (0.48) | APOBEC3GSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11630430 | 0.80 | SLC6A4 (0.54) | APOBEC3GSLC6A4SLC6A2SLC6A3LMNA | |
| SCHEMBL11632678 | 0.80 | SLC6A4 (0.58) | APOBEC3GSLC6A4SLC6A2IFNAR1SLC6A3 | |
| SCHEMBL4448364 | 0.79 | APOBEC3G (0.59) | APOBEC3GSLC6A4SLC6A2LDHAIFNAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| WO-2007081978-A2 | MODULATORS OF HEPATOCYTE GROWTH FACTOR / C-MET ACTIVITY | ANGION BIOMEDICA CORPORATION (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | APOBEC3G 4882/4885SLC6A4 994/4885SLC6A2 1776/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | APOBEC3G 4882/4885SLC6A4 1078/4885SLC6A2 2127/4885 |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | APOBEC3G 4882/4885SLC6A4 1078/4885SLC6A2 2127/4885 |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | APOBEC3G 2145/4885SLC6A4 3549/4885SLC6A2 4068/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | APOBEC3G 4882/4885SLC6A4 1078/4885SLC6A2 2127/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | APOBEC3G 4882/4885SLC6A4 994/4885SLC6A2 1776/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | APOBEC3G 4882/4885SLC6A4 975/4885SLC6A2 1765/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | APOBEC3G 4882/4885SLC6A4 1137/4885SLC6A2 2157/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | APOBEC3G 4882/4885SLC6A4 1078/4885SLC6A2 2127/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | APOBEC3G 2907/4885SLC6A4 3112/4885SLC6A2 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.